E-Book

E-Book 2nd Congress

  • Comparison of AstraZeneca and Sinopharm in protection against COVID-19 infection
  • Arash Letafati,1,* Marjan Fatahinasab,2 Fatemeh Mojtahedi ,3
    1. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    2. Department of basic sciences, Microbiology, Tabriz University, Tabriz, Iran
    3. Department of Immunology, Yazd University, Yazd, Iran


  • Introduction: Acute Respiratory Infections (ARIs) are the most prevalent diseases that affected individuals of all ages worldwide. Multiple viruses cause ARIs including coronaviruses. The global burden of the SARS-CoV-2 pandemic evaluated about 45 million confirmed cases including over 6 million deaths. Studies showed that two doses of vaccination play an important role in decreasing hospitalization and mortality rate among patients but the efficacy of a booster dose is also important. We aimed to show which type of vaccine causes better immunity and fewer symptoms manifestation against Omicron as a booster dose.
  • Methods: We conducted a cross-sectional study on individuals who were admitted to the hospital with respiratory symptoms. Possible SARS-CoV-2 infection by using Real-time PCR was conducted and after that, We have limited the study to infected people with a history of 3 doses of vaccination, injected 2 doses of BIBP (Sinopharm) and a similar or different booster dose, BIBP or AZD1222 (AstraZeneca), and inquired them about their age, gender, type of injected vaccine for the third dose, and all respiratory symptoms of these patients were investigated.
  • Results: Among 346 cases, 120 cases were positive for SARS-CoV-2 but vaccinated with two doses of Sinopharm and a different booster doses of AZD1222 or BIBP were 94 among these 120 cases. patients vaccinated with AZD1222 as a booster dose showed fewer symptoms compared to those vaccinated with three doses of BIBP.
  • Conclusion: As a result, the patients vaccinated with 2 doses of BIBP and AZD1222 as a booster dose(n=26) manifested mild symptoms to those who were vaccinated with 3 doses of BIBP(n=68). Therefore, our study showed injecting a booster dose will help in decreasing hospitalization and severity of the infection, and also it seems that the third dose of vaccination with AZD1222 is better than BIBP and it is suggested to make better immunity against SARS-CoV-2.
  • Keywords: ARIs, COVID-19, SARS-CoV-2, Sinopharm, AstraZeneca